On March 22, British Columbia’s Ministry of Health announced that three new enoxaparin biosimilars, Valero Pharmaceuticals’ REDESCA, Juno Pharmaceuticals’ NOROMBY, and Sandoz’s INCLUNOX, would be covered by PharmaCare, the province’s public health plan.  Enoxaparin is a blood thinner that is used for the prevention and treatment of blood clot disorders.  The reference product LOVENOX, a…